Citigroup analyst Yigal Nochomovitz upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Neutral to Buy.
Carvana Shoots Higher After Q2 Earnings – Here’s Why
Carvana Co (NYSE: CVNA) reported a second-quarter FY23 sales decline of 23.6% year-on-year to $2.97 billion, beating the consensus